For instance, Trametinib, a Mek inhibitor, reduces the renal disease burden in Tns1-KO mice [8] and dihydro-CDDO-trifluoroethyl amide, a bardoxolone methyl analog, suppresses tubular epithelial cell injury, chronic inflammation, and fibrosis, but not glomerular defects in ICGN mice with Tns2 mutation [82]. The gene discussed is MAP2K7; the disease is kidney disorder.